Open AccessKinetics and prognostic value of soluble VCAM‐1 in ST‐segment elevation myocardial infarction patients
Author(s) -
Hayek Ahmad,
Paccalet Alexandre,
Mechtouff Laura,
Da Silva Claire C.,
Ivanes Fabrice,
Falque Hadrien,
Leboube Simon,
Varillon Yvonne,
Amaz Camille,
Bourguig Charles,
Prieur Cyril,
Tomasevic Danka,
Genot Nathalie,
Derimay François,
BonnefoyCudraz Eric,
Bidaux Gabriel,
Mewton Nathan,
Ovize Michel,
Bochaton Thomas
Publication year - 2021
Publication title -
immunity, inflammation and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 18
ISSN - 2050-4527
DOI - 10.1002/iid3.409
Subject(s) - medicine , ejection fraction , cardiology , hazard ratio , myocardial infarction , confidence interval , area under the curve , clinical endpoint , receiver operating characteristic , revascularization , percutaneous coronary intervention , creatine kinase , heart failure , clinical trial
Background Soluble vascular cell adhesion molecule‐1 (sVCAM‐1) is a biomarker of endothelial activation and inflammation. There is still controversy as to whether it can predict clinical outcome after ST‐elevation myocardial infarction (STEMI). Our aim was to assess the sVCAM‐1 kinetics and to evaluate its prognostic predictive value. Method We prospectively enrolled 251 consecutive STEMI patients who underwent coronary revascularization in our university hospital. Blood samples were collected at admission, 4, 24, 48 h and 1 month after admission. sVCAM‐1 serum level was assessed using ELISA assay. All patients had cardiac magnetic resonance imaging at 1‐month for infarct size (IS) and left ventricular ejection fraction (LVEF) assessment. Clinical outcomes were recorded over 12 months after STEMI. Results sVCAM‐1 levels significantly increased from admission up to 1 month and were significantly correlated with IS, LVEF, and LV end‐systolic and diastolic volume. (H48 area under curve (AUC) ≥ H48 median) were associated with an increased risk of adverse clinical events during the 12‐month follow‐up period with a hazard ratio (HR) = 2.6 (95% confidence interval [CI] of ratio = 1.2–5.6, p = .02). The ability of H48 AUC for sVCAM‐1 to discriminate between patients with or without the composite endpoint was evaluated using receiver operating characteristics with an AUC at 0.67 (0.57–0.78, p = .004). This ability was significantly superior to H48 AUC creatine kinase ( p = .03). Conclusions In STEMI patients, high sVCAM‐1 levels are associated with a poor clinical outcome. sVCAM‐1 is an early postmyocardial infarction biomarker and might be an interesting target for the development of future therapeutic strategies.